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ABSTRACT
Granulocyte macrophage-colony stimulating factor
(GM-CSF) is produced by T cells, but not B cells,
in response to immune signals. GM-CSF gene
activation in response to T-cell stimulation requires
remodelling of chromatin associated with the
gene promoter, and these changes do not occur in
B cells. While the CpG methylation status of the
murine GM-CSF promoter shows no correlation with
the ability of the gene to respond to activation, we
find that the basal chromatin environment of the
gene promoter influences its ability to respond to
immune signals. In unstimulated T cells but not B
cells, the GM-CSF promoter is selectively marked
by enrichment of histone acetylation, and associa-
tion of the chromatin-remodelling protein BRG1.
BRG1 is removed from the promoter upon activa-
tion concomitant with histone depletion and BRG1
is required for efficient chromatin remodelling and
transcription. Increasing histone acetylation at
the promoter in T cells is paralleled by increased
BRG1 recruitment, resulting in more rapid chromatin
remodelling, and an associated increase in GM-CSF
mRNA levels. Furthermore, increasing histone
acetylation in B cells removes the block in chro-
matin remodelling and transcriptional activation
of the GM-CSF gene. These data are consistent
with a model in which histone hyperacetylation
and BRG1 enrichment at the GM-CSF promoter,
generate a chromatin environment competent
to respond to immune signals resulting in gene
activation.
INTRODUCTION
Highly dynamic changes in gene expression are a feature
of the immune system, where the orchestration of an
immune response to invading pathogens relies on rapid
induction of cytokine gene expression. However, a key
feature of cytokine gene expression is that many cyto-
kines are expressed in a cell-type restricted fashion. For
example, granulocyte macrophage-colony stimulating
factor (GM-CSF) which plays a key role in myeloid cell
production and function is induced in a range of cell types
including T cells, macrophages, endothelial cells and
ﬁbroblasts, but not B cells, in response to immune or
inﬂammatory signals (1). The combination of transcrip-
tion factor-binding sites found in the promoters and
enhancers of cytokine genes and the availability of these
transcription factors in particular cell types is an
important factor in the cell-type speciﬁc expression
patterns of cytokines. However, it is clear that the
chromatin environment of cytokine genes can also dictate
the ability of transcription factors to access the control
regions of genes (2,3), and therefore provides an
additional level at which cell-type speciﬁc gene expression
can be controlled.
DNA methylation, histone modiﬁcations and variants
and also the location and density of nucleosomes can
all contribute to the generation of a speciﬁc epigenetic
environment that can determine the competency of a
gene to respond to activating signals (4). It is now well
established that many cytokine genes are found in a
relatively inaccessible chromatin environment and the
activation of gene expression requires the reorganization
of chromatin structure to a more accessible form (2,3).
For example, it has long been known that activation
of both the GM-CSF and IL-2 genes following T-cell
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activation is accompanied by the appearance of DNase I
hypersensitive (DH) sites in promoter and enhancer
regions (5–7). The appearance of these DH sites correlates
well with the ability of the GM-CSF gene to be activated
in diﬀerent cell types (8), and therefore it is likely that
these chromatin remodelling events contribute to the cell-
type speciﬁcity of gene expression. It is now clear that the
appearance of DH sites across the IL-2 promoter and
GM-CSF promoter and enhancer reﬂect highly localized
changes in chromatin structure, involving the selective
disruption of one or two nucleosomes (9–12), and these
events were recently shown to involve the depletion of
histones from these regions (13,14). However, the mecha-
nisms involved in eviction of histones from the GM-CSF
and IL-2 promoters in response to T-cell activating signals
remain to be elucidated. Furthermore, it is not clear
how these histones are speciﬁcally targeted for depletion
in T cells and whether they are diﬀerentially marked in
particular cell types to enable their remodelling.
Changes in chromatin structure which facilitate gene
activation can be brought about by two general mechan-
isms. First, histone proteins are subject to a range of
modiﬁcations, including acetylation, phosphorylation
and methylation, which may alter higher order chromatin
structure directly or act as binding sites for non-histone
proteins that are able to modify chromatin structure and
function (15,16). The association of histone acetylation
with gene activation has been well documented at many
individual genes, e.g. (17,18) as well as in a number of
genome-wide studies (19–21). Secondly, a number of
diﬀerent complexes that are able to harness the energy
from ATP hydrolysis to remodel nucleosomes have been
described (22). The best characterized of these is the SWI/
SNF complex, which has been implicated in the activa-
tion of a number of inducible genes. For example, the
SWI/SNF complex is required for the activation of the
myogenin gene during myoD-induced muscle diﬀeren-
tiation (23) and has been demonstrated to contribute
to activation of a number of pro-inﬂammatory genes
following macrophage activation (24).
The importance of histone modiﬁcations and chro-
matin remodelling complexes in bringing about changes in
chromatin structure is now well established and the precise
series of events involved in remodelling nucleosomes to
facilitate inducible gene transcription are understood in
detail for several genes. The best described of these are
the response of the IFN-b gene to viral infection, and the
yeast Pho5 and Pho8 genes to low phosphate concentra-
tions. In both these cases, changes in chromatin structure
are facilitated by stimulus-driven local increases in histone
acetylation and recruitment of the SWI/SNF remodelling
complex (25–28).
Activation of the GM-CSF cytokine gene in response to
T-cell activating stimuli is accompanied by the selective
depletion of histones from the promoter (13), reminiscent
of that observed at the Pho5 promoter (29,30). Here we
demonstrate a role for local histone acetylation and the
SWI/SNF ATPase BRG1 in activation of the murine
GM-CSF gene. However, in contrast to the genes
described above, BRG1 is not recruited to the promoter
in response to T-cell activating signals, but rather is poised
at the GM-CSF promoter in unstimulated EL-4T cells.
Similarly, histone acetylation does not increase at the
GM-CSF promoter in response to T-cell activation, but is
already enriched at the GM-CSF promoter in unstimu-
lated T cells. These marks are not present at the GM-CSF
promoter in B cells, in which gene expression is not
inducible. These data suggest that both BRG1 and histone
acetylation are involved in generating a transcriptionally
competent environment at the GM-CSF promoter and
this environment contributes to the cell-type speciﬁc
expression of GM-CSF in immune cells.
MATERIALS AND METHODS
Plasmids
The BRG1 construct pBJ5-BRG1K/R was provided by
Dr G. Crabtree and the mouse GM-CSF constructs,
AOGM and pGM0.2, were provided by Dr P. Cockerill,
and have been described previously (31,32).
Cell culture
Murine EL-4T cells were cultured in RPMI as described
previously (9). Murine A20 and WEHI231 B cells were
cultured in DMEM supplemented with 10% fetal bovine
serum (JRH Biosciences, USA), 2mM L-glutamine (CSL,
Australia), 100U/ml penicillin, 100 mg/ml streptomycin
(CSL) and 0.05mM 2-mercaptoethanol (Sigma-Aldrich,
USA) at 378C and 5% CO2. Cells were stimulated with
20 ng/ml phorbol 12-myristate 13-acetate (PMA,
Boehringer Mannheim, Germany) and 1 mM calcium
ionophore (A23187; Sigma–Aldrich). Cells were pre-
treated with 200 ng/ml trichostatin A (TSA, Sigma–
Aldrich) for 4–16 h, and were treated with 2-deoxy-5-
azacytidine (Sigma–Aldrich) at 0.25mM for 24 h, at which
point the treatment was removed and the cells grown for a
further 24 h.
Primary cells were extracted from the spleens of 8-week-
old male C57B6 mice. Spleens were homogenized, and
leucocytes were then isolated by density gradient centri-
fugation in Lympholyte-M (Cedarlane, USA) according
to manufacturer’s instructions. CD4+ T cells and CD19+
B cells were magnetically separated from the leucocytes
using CD4 (L3T4) or CD19 MicroBeads and MS MACS
columns (Miltenyi Biotec, Germany) following the man-
ufacturer’s instructions. Cells were cultured in DMEM
supplemented with 10% fetal bovine serum (JRH
Biosciences), 2mM L-glutamine (CSL), 100U/ml penicil-
lin, 100 mg/ml streptomycin (CSL), 1mM sodium
pyruvate, 10mM HEPES (Sigma–Aldrich) and 0.05mM
2-mercaptoethanol (Sigma–Aldrich) at 378C and 5% CO2.
Cells were stimulated as described above for cell lines.
Transfection and luciferase reporter assay
EL-4 and A20 cells (4.5 106) were transfected with 5 mg
of pGL3-Control (Promega, USA) or 10 mg of GM0.2
plasmid at 270V and 975 mF using a Bio-Rad Gene Pulser
X Cell as previously described (33). At 24 h post-
transfection, cells were stimulated with PMA and calcium
ionophore for 8 h. Protein was isolated, quantitated by
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Bradford assay (Bio-Rad, USA) and 30 mg of protein
analysed for luciferase activity (Luciferase assay kit,
Promega) using a Turner Biosystems VeritasTM Micro-
plate Luminometer. CpG methylated pGM0.2 plasmid
was prepared for transfections by incubating 150 mg of
plasmid with 200U of M.SssI methylase (New England
Biolabs, USA) and 640 mM S-adenosylmethionine for 3 h
at 378C, followed by phenol–chloroform extraction and
ethanol precipitation.
Sorting transfected cells
EL-4T cells were co-transfected by electroporation with
8 mg of either pBJ5 or pBJ5-BRG1K/R plasmids along
with 3 mg of KKII selection plasmid (Miltenyi Biotech).
Transfected cells were enriched 24 h post-transfection
using the MACSelect transfected cell selection kit accord-
ing to the manufacturer’s instructions (Miltenyi Biotech).
Nuclear extracts and western blotting
Nuclear extracts were prepared by a modiﬁcation of the
method of Schreiber et al. (34), as described previously
(35). Nuclear proteins were separated by SDS–PAGE
through 12% polyacrylamide, transferred onto nitrocellu-
lose membrane and subjected to western blot analysis
using anti-HA (Sigma–Aldrich), anti-AcH3 (Upstate
Biotech, USA), anti-Sp1, anti-p65, anti-cRel and anti-
BRG1 (Santa Cruz Biotechnology, USA) antibodies and
the corresponding peroxidase-conjugated secondary anti-
bodies (DAKO, Denmark). Proteins were visualized using
the Supersignal West Pico Chemiluminescent kit (Pierce,
USA).
RNA isolation and real-time PCR analysis
Total RNA was isolated using Tri-Reagent (Sigma) and
reverse transcribed using Superscript II Reverse
Transcriptase (Life Technologies, USA), and SYBR
Green PCR ampliﬁcation performed on the Rotor-Gene
2000 real-time cycler (Corbett Research, Australia) using
the QuantiTect SYBR Green PCR kit (Qiagen, USA), as
described previously (35) PCR was conducted using GM-
CSF primer set +II and in parallel using the GAPDH
primers (Table 1) to normalize for diﬀerences in cDNA
synthesis and RNA input. To correlate the threshold (Ct)
values from the ampliﬁcation plots to copy number, a
standard curve was generated using the mouse GM-CSF
plasmid AOGM (31) and pCR2.1-GAPDH plasmid (35).
PCR product melt curves were analysed for a single peak
and the products visualized by agarose gel electrophoresis
and ethidium bromide staining to ensure that a single
product was generated in the PCR.
CHART-PCR (chromatin accessibility by real-time PCR)
Accessibility of DNA to digestion with restriction enzymes
and micrococcal nuclease (MNase) was analysed using
CHART-PCR (9). Cell nuclei (5 106 nuclei per 100 ml)
were treated with 150U HinfI enzyme (New England
BioLabs) at 378C for 45min or with 25U MNase (Roche
Boehringer Mannheim, Germany) for 5min at 208C. In
each case, control samples without enzyme were incubated
similarly to monitor for endonuclease activity. Genomic
DNA was subsequently isolated using a QIAamp blood kit
(Qiagen), and analysed by SYBR Green quantitative PCR
in a total volume of 25 ml using the QuantiTect SYBR
Green PCR kit (Qiagen). The primer sequences are shown
in Table 1. Accessibility was determined by correlating the
Ct-values from the ampliﬁcation plots to a standard curve
generated with the AOGMplasmid, and was expressed as a
percentage of undigested genomic DNA for each primer
set.
Methylation assay
Genomic DNA was isolated from cell lines using the
QIAamp Blood Kit (Qiagen) and 1 g was mock digested or
digested with AciI (1U, New England Biolabs) for 16 h at
378C. DNA (50 ng) was analysed by quantitative PCR
using primer sets as shown in Table 1. Percent methylation
was determined by correlating the Ct-values from the
ampliﬁcation plots to a standard curve generated with the
AOGM plasmid and was expressed as a percentage of
the mock digested genomic DNA for each primer set.
Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed as previously described (13).
Brieﬂy, chromatin from formaldehyde ﬁxed cells was
fragmented to a size range of 100–500 bp. Solubilized
chromatin was immunoprecipitated with 4 mg of antibody
against acetylH3 and acetylH3K9 (Upstate Biotechnol-
ogy), 1.5 mg anti-acetylH4 and anti-histone H3 (Abcam)
or 1 mg anti-Brg1 antibody (Santa Cruz Biotechnology).
Immune complexes were recovered using salmon
sperm DNA/protein A-agarose, washed and eluted.
Following cross-link reversal and proteinase K treatment,
Table 1. Primers used for CHART-PCR, ChIP or mRNA measurements by quantitative PCR
Primer set Sense (50–30) Anti-sense (50–30)
50 GAGCTTCTGGAGAGGGAGGT TCCCAGGCTTAGTCTGTTGC
V TGGAATGAGCCACCAGAGTA GGCTCTTGCTTCCATAGCAC
I GCCTGACAACCTGGGGGAAG TGATTAATGGTGACCACAGAACTC
+I GAGTTCTGTGGTCACCATTAATCA CACATCCTCCTCAGGACCTT
+II AAGGTCCTGAGGAGGATGTG GAGGTTCAGGGCTTCTTTGA
30 ATTTGGGCATAGGTGGAGTG CCTCGATTTCACCTCCCTTT
ESP1 GTCACTCCACCCATCTGGTC AGGCATTCCTAGATTGCACG
GAPDH AAGTATGATGACATCAAGAAGGTGGT AGCCCAGGATGCCCTTTAGT
RhoM GCAGCTGGTCTTCACAGTCA GAAGTCACCCGCATGGTTAT
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immunoprecipitated DNA was puriﬁed by phenol–chloro-
form extraction and ethanol precipitation. DNA was
re-suspended in 50 ml MilliQ water and ampliﬁed by real-
time PCR. Data were analysed relative to no antibody
control immunoprecipitates and normalized to total input
samples.
RESULTS
GM-CSFmRNA expression and promoter chromatin
remodelling are blocked in B cells
GM-CSF mRNA expression can be rapidly induced in
T cells by treatment with the phorbol ester, PMA and
calcium ionophore (P/I), which activates the PKC and
calcium signalling pathways, respectively. For example,
P/I treatment of the murine EL-4T cell line for 4 h
resulted in an increase in GM-CSF mRNA levels, as
measured by quantitative PCR analysis (Figure 1B). In
contrast, little GM-CSF mRNA expression was detected
in the murine A20 and WEHI-231 B-cell lines in response
to P/I treatment (Figure 1B). Similarly, GM-CSF mRNA
expression was induced in response to P/I treatment in
murine splenic CD4+ T cells, but not splenic B cells
(Figure 1C).
To determine whether this may be due to diﬀerences
in GM-CSF promoter activity, a luciferase reporter
construct containing the mouse GM-CSF promoter (31)
was transfected into EL-4T cells or A20 B cells and
luciferase activity measured. In both cell types, promoter
activity increased 6-fold following stimulation of the
cells with P/I for 8 h, although basal activity was
considerably lower in A20 B cells compared with the
EL-4T cells (Figure 1D). Both cell lines demonstrated
approximately equal activity of a control reporter plasmid
driven by the SV40 promoter (pGL3-Control) demon-
strating equal transfection eﬃciency (data not shown).
Therefore, while expression of mRNA from the endogen-
ous GM-CSF gene is blocked in B cells, the GM-CSF
promoter responds to P/I stimulation in a reporter assay
with equal eﬃciency in both cell types.
We have previously shown that induction of GM-CSF
mRNA expression in T cells in response to P/I stimulation
requires the speciﬁc depletion of histones from the gene
promoter, resulting in its increased accessibility (11,13).
To determine whether these chromatin remodelling events
also occur across the GM-CSF promoter in B cells,
accessibility of the promoter to MNase was examined
using a quantitative PCR-based assay [CHART-PCR,
(9)]. EL-4T cells and A20 B cells were either left
unstimulated or stimulated with P/I for 4 h, nuclei
isolated, incubated with MNase and genomic DNA
isolated. The accessibility of the GM-CSF promoter was
then monitored by PCR ampliﬁcation of the genomic
DNA using primer set I (Figure 1A), with the amount of
PCR product generated from digested samples plotted as a
percentage of the amount generated from undigested
genomic DNA samples. As described previously (11), a
relatively high level of basal accessibility was observed at
the GM-CSF promoter in unstimulated EL-4T cells
(Figure 1E), which increased following P/I treatment.
However, while an equivalent level of inherent accessi-
bility was observed at the promoter in unstimulated
A20 B cells (Figure 1E), no change in accessibility was
observed following stimulation (Figure 1E). Therefore,
the chromatin remodelling events at the promoter that
accompany transcriptional activation of the GM-CSF
gene in T cells are blocked in B cells.
We have previously shown that the NF-kB family of
proteins are important for chromatin remodelling of the
GM-CSF promoter in response to T-cell activation (11,35)
and it was possible that these transcription factors were
not expressed as eﬃciently in B cells. Therefore, the
nuclear level of the NF-kB proteins, cRel and RelA, was
determined by western analysis in the B- and T-cell lines.
Little or no RelA and cRel was present in the nucleus of
unstimulated T and B cells, but nuclear accumulation of
the proteins was observed in both cell types following P/I
stimulation for 4 h (Figure 1F). Reanalysis of the western
blot with an antibody to the constitutively expressed Sp1
protein conﬁrmed equal protein loading (Figure 1F).
Therefore, although the GM-CSF promoter is capable
of responding to an activation signal in a reporter assay
and NF-kB proteins are equally represented in both B and
T cells, chromatin remodelling events at the GM-CSF
promoter that precede transcriptional activation in T cells
are blocked in B cells. These results raised the possibility
that the failure of the endogenous GM-CSF gene to
respond to activating signals in B cells was due to
diﬀerences in chromatin status of the gene in B cells
compared to T cells.
CpGmethylation status of the GM-CSF promoter
does not correlate with gene activity
Methylation of CpG dinucleotides within regulatory
elements of genes is well established as an epigenetic
mechanism that contributes to gene repression (36) and we
therefore hypothesized that the GM-CSF promoter may
be marked by diﬀerential methylation in T and B cells.
A single CpG site located within the GM-CSF proximal
promoter (Figure 1A) overlapping an Sp1-binding site
located within the CD28-responsive region (CD28RR) of
the promoter (37) and a second site at +100 are both
contained within recognition sites for the methylation
sensitive Aci1 restriction enzyme, and therefore methyla-
tion of these sites was examined using a restriction
enzyme-based assay. Genomic DNA was isolated from
EL-4T cells, A20 and WEHI-231 B cells as well as
primary CD4+ T cells and B cells isolated from mouse
spleen, digested with Aci1 and analysed by quantitative
PCR using primer sets that covered each of the CpG sites
(Figure 1A). The amount of PCR product generated from
digested samples was plotted as a percentage of the
amount generated from undigested genomic DNA sam-
ples, generating a measure of methylation at each site.
The promoter Site-1 was completely methylated in the
two B-cell lines and in both primary T and B cells but was
only partially methylated in EL-4T cells (Figure 1A). The
Site+1 within the transcribed region was completed
methylated in the two B-cell lines but only partially
methylated in EL-4 cells and both of the primary cell types
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(Figure 1A). Thus, the methylation status of these sites
varies considerably between primary cells and cell lines
and there appears to be no correlation between the
methylation status of these sites and the ability of the gene
to be expressed.
The eﬀect of demethylating these sites in T- and B-cell
lines was next examined. EL-4T cells and A20 B cells were
treated with 2-deoxy-5-azacytidine (azaC) to reduce CpG
methylation. While azaC treatment decreased methylation
of the promoter CpG site in both EL-4T cells and A20 B
cells (to 20 and 30% methylation, respectively, Figure 2B),
it augmented P/I stimulation in EL-4T cells only
(4-fold, Figure 2C) and had no eﬀect on GM-CSF
expression in A20 B cells, either alone or following P/I
stimulation (Figure 2C). Therefore, demethylation of the
promoter in B cells is not suﬃcient to relieve the block
in transcriptional activation of the GM-CSF gene in
these cells.
A
+1−100−200−300−400 +100
NFAT/EtsAP1Sp1κBCK-1
CD28RR
+1−100
Site −1 Site +1
−I
−II−V +II
+I
5′ 3′
D
EL-4 A20
1000
2000
3000
4000
R
el
at
iv
e 
lu
ci
fe
ra
se
 u
ni
ts
0
PI
NS
100
75
50
0
25
%
 a
cc
es
sib
ili
ty
 M
N
as
e
NS P/I P/INS
EL4 A20
E
EL-4
NS
EL-4
P/I
A20
NS
A20
P/I
Sp1
RelA
cRel
F
C
NS NSP/I P/I
0
1000
2000
3000
4000
(co
pie
s G
M
-C
SF
)/(
co
pie
s G
AP
DH
)
x
10
00
0
 
T-cell B-cell
B
EL-4 A20 WEHI-231
40
80
120
160
200
(co
pie
s G
M
-C
SF
)/(
co
pie
s G
AP
DH
)
x
10
00
0
 
0
Figure 1. GM-CSF expression in T cells versus B cells. (A) Schematic representation of the GM-CSF promoter showing transcription factor-binding
sites, CpG sites and the CD28RR. DNA fragments ampliﬁed by various primer sets are indicated and numbered with roman numerals. (B and C)
mRNA isolated from P/I stimulated EL-4, A20 and WEHI-231 cells (B) or primary CD4+ T and CD19+ B cells (C) was reverse transcribed and
ampliﬁed by PCR using GM-CSF speciﬁc primers. The data are expressed as copies of GM-CSF per copies of GAPDH. The mean and standard
error of three (cell lines) or two (primary cells) independent experiments are shown. (D) EL-4T cells and A20 B cells were transfected with a GM-
CSF promoter luciferase reporter construct and stimulated with P/I. Protein was extracted and luciferase activity monitored. The mean and standard
error of three independent experiments are shown. (E) Nuclei isolated from non-stimulated and P/I stimulated EL-4T cells and A20 B cells were
incubated with MNase and accessibility to the GM-CSF promoter determined by CHART-PCR. The mean and standard error of three independent
experiments are shown. (F) Nuclear extracts prepared from non-stimulated and P/I stimulated EL-4T cells and A20 B cells were subjected to western
analysis using the indicated antibodies.
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Put together, these data suggest that the methylation
status of the GM-CSF promoter does not inﬂuence the
ability of the GM-CSF promoter to undergo chromatin
remodelling and gene transcription in response to activat-
ing signals and that demethylation of the promoter in B
cells is not suﬃcient to relieve the block in transcription
activation.
GM-CSF promoter is hyperacetylated in T cells
compared to B cells
The association between histone acetylation and gene
transcription is well established, both from studies of
individual genes, as well as global gene analysis studies
(17–21). We, therefore, speculated that diﬀerences in
histone acetylation at the GM-CSF promoter may account
for diﬀerences in the transcriptional competence of the
promoter in T and B cells. To investigate this possibility,
ChIP analysis was used to map histone acetylation levels
across diﬀerent regions of the GM-CSF gene in unstimu-
lated EL-4 T cells. DNA immunoprecipitated with
acetylated-H3K9 antibodies was ampliﬁed by quantitative
PCR using primer sets that covered various regions of the
GM-CSF gene (Figure1A). H3K9 acetylation was enriched
at regions surrounding and including the GM-CSF
promoter (primer sets V, II, I, +I) compared to
regions>2-kb upstream or downstream from the promoter
(primer sets 50 and 30), a region of the GM-CSF enhancer
(ESP1) and the constitutively expressed GAPDH gene
(Figure 3A). The acetylation level of GAPDH is still at
least 5-fold higher than a non-expressed gene (rhodopsin)
where there is barely detectable acetylation (data not
shown). The enrichment of histone acetylation at the
promoter was highlighted when the level of acetylation was
plotted relative to histone occupancy levels (Figure 3B).
A similar pattern was observed for H4 acetylation (data
not shown).
To determine whether there is a further increase in
acetylation at the promoter following activation, histone
H3 and Ac-H3K9 levels were measured in EL-4 cells at
various times following activation with P/I. As previously
described (13), the level of Ac-H3K9 and as well as total
H3 decreased at the promoter following activation
(Figure 3C and D). While there was some ﬂuctuation at
early time points, when AcH3K9 was plotted relative to
total H3 there was no evidence for either a signiﬁcant
increase or decrease in acetylation across the GM-CSF
promoter (Figure 3E). Therefore, reduced acetylation
observed at the promoter in response to stimulation
reﬂects nucleosome depletion rather than histone
deacetylation.
To determine whether the higher level of acetylation at
the promoter in non-stimulated EL-4 cells correlates with
the transcriptional competence of the GM-CSF gene,
histone H3 acetylation levels at the GM-CSF promoter
were examined in EL-4T cells compared to A20 and
WEHI-231 B cells. We found that histone H3 acetylation
at the GM-CSF promoter (primer set I) was almost 50%
lower in both of the B-cell lines in which GM-CSF
expression is not inducible compared to EL-4T cells
(Figure 3F). This result was conﬁrmed in primary mouse
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Figure 2. Methylation status of the GM-CSF promoter and enhancer
in T cells and B cells. (A) Genomic DNA was isolated from EL-4T
cells, A20 and WEHI-231 B cells and primary CD4+ T and CD19+ B
cells, and digested with the methylation sensitive AciI enzyme. Digested
and undigested DNA was analysed by quantitative PCR using the
indicated primer sets. The mean and standard error of three
independent experiments are shown. (B) Genomic DNA was isolated
from EL-4T cells and A20 B cells either left untreated or pre-treated
with azaC. Promoter methylation was determined using primer set I.
The mean and standard error of three independent experiments are
shown. (C) mRNA was isolated from EL-4T cells and A20 B cells
treated as in (B) prior to stimulation with P/I. cDNA was prepared and
GM-CSF expression levels monitored by PCR using primer set +II.
The mean and standard error of three independent experiments are
shown.
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cells, with splenic B cells also displaying 50% lower
histone H3 acetylation levels compared to CD4+ T cells
(Figure 3G).
While there is no evidence for an increase in acetylation
following activation, enriched histone acetylation marks
the GM-CSF promoter relative to ﬂanking regions in a
T-cell line. Promoter acetylation is also higher in primary
T cells and a T-cell line compared to B cells and may play
a role in the ability to remodel promoter chromatin.
Hyperacetylation of the GM-CSF promoter facilitates
chromatin remodelling and transcription in both T and B cells
To determine whether histone acetylation facilitates trans-
criptional activation of the GM-CSF gene, we examined
GM-CSF expression in EL-4T cells treated with the
histone deacetylase inhibitor, TSA. As expected TSA
treatment of EL-4T cells caused a dramatic increase in
global acetylated H3 levels, as measured by western
blotting of nuclear extracts (Figure 4A) but global
BA
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
GAPDH ESP1 3′ −V −II −I +I 5′ GAPDH ESP1 3′ −V −II −I +I 5′
H
ist
on
e 
ac
et
yl
at
io
n
(%
 to
tal
 in
pu
t)
A
ce
ty
la
tio
n 
re
la
tiv
e
to
 to
ta
l  
hi
sto
ne
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
F
EL-4 A20 WEHI-231
0.2
0.4
0.6
0.8
1.0
1.2
0
R
el
at
iv
e 
H
ist
on
e 
H
3 
ac
et
yl
at
io
n
0
0.5
1
1.5
2
0 2 4 6 8 10 12 14 16 18 20 22
Time (h)
0 2 4 6 8 10 12 14 16 18 20 22
Time (h)
0 2 4 6 8 10 12 14 16 18 20 22
Time (h)
R
el
at
iv
e 
hi
sto
ne
 a
ce
ty
la
tio
n
AcH3K9 −I
AcH3K9 −V
0
0.5
1
1.5
2
A
ce
ty
la
tio
n 
re
la
tiv
e
to
 to
ta
l h
ist
on
e
-I
-V
E
C D
R
el
at
iv
e 
H
3 
oc
cu
pa
nc
y
0
0.2
0.4
0.6
0.8
1
1.2
−V
−I
R
el
at
iv
e 
H
ist
on
e 
H
3 
ac
et
yl
at
io
n
0.2
0.4
0.6
0.8
1.0
1.2
0
T cell B cell
G
Figure 3. Histone acetylation is enriched at the GM-CSF promoter in T cells. (A) ChIP assays were performed with anti-acH3K9 antibodies on
unstimulated EL-4T cells. Immunoprecipitated DNA was ampliﬁed using the indicated primer sets (described in Figure 1A). The data are presented
as the ratios of immunoprecipitated DNA to total input. The mean and standard error of three independent experiments are shown. (B) Histone
acetylation levels [from (A)] presented as a ratio of total H3 levels. (C, D) ChIP assays were performed with anti-acetylated H3K9 (C) or core H3 (D)
antibodies on EL-4T cells stimulated with P/I for the indicated times. Immunoprecipitated DNA was ampliﬁed with primer sets as indicated. The
data are presented as the ratios of immunoprecipitated DNA to total input and normalized to the unstimulated cell samples, which was set at 1. The
mean and standard error of three independent experiments are shown. (E) AcH3K9 levels [from (C)] presented as a ratio of total H3 levels. (F) EL-
4T cells, A20 and WEHI-231 B cells were subjected to ChIP analysis using an anti-acH3 antibody. Immunoprecipitated DNA was ampliﬁed using
primer set -I. Data are plotted as acetylation level relative to EL-4T cells. The mean and standard error of three independent experiments are shown.
(G) ChIP analysis as above was also performed using primary CD4+ T and CD19+ B cells. Data are plotted as acetylation relative to primary T cell.
The mean and standard error of two independent experiments are shown.
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acetylation levels were not aﬀected by P/I stimulation
(Figure 4A). This increase in global histone acetylation in
response to TSA treatment was reﬂected by a similarly
dramatic increase in acetylated H3K9 levels across the
GM-CSF gene, as determined by ChIP assay (Figure 4B),
both at the promoter (primer set I and +I) and
upstream regions (set V). We have previously demon-
strated that acetylated histone levels decrease across the
GM-CSF promoter in T cells following stimulation due to
the speciﬁc depletion of histones from this region [(13) and
Figure 3C]. Consistent with this, a decrease in acetylated
histones was observed at the promoter region (primer set
I and +I) in TSA-treated cells following P/I stimulation
(Figure 4B). Although not observed normally (13), a
decrease in acetylated histones was also observed to some
extent at the upstream region (primer set V, Figure 4B)
in the TSA-treated cells suggesting that acetylation may
facilitate histone removal following activation.
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Figure 4. Histone hyperacetylation facilitates GM-CSF gene activation in T cells. (A) Nuclear extracts from EL-4T cells pre-treated with TSA for 4 h
followed by P/I treatment for 4 h as indicated, were subjected to SDS–PAGE and analysed by western blotting with the indicated antibodies.
(B) ChIP assays were performed with an antibody against acetylated H3K9 on EL-4T cells treated with or without TSA and then either unstimulated
(NS) or stimulated with P/I for the indicated times. Immunoprecipitated DNA was analysed by PCR using primer sets as indicated. Data are
graphed as ratios of the immunoprecipitated sample to total input sample. The mean and standard error of three independent assays are shown.
(C) GM-CSF mRNA levels were determined by PCR analysis of cDNA prepared from EL-4T cells treated with or without TSA for 4 h and then
either unstimulated (NS) or stimulated with P/I for 4 h. (D) Rhodopsin mRNA levels were determined by PCR analysis of EL-4 cells treated with or
without TSA for 4 h, and then either unstimulated (NS) or stimulated with P/I for 4 h. The mean and standard error of three independent
experiments are shown. (E) Nuclei were isolated from EL-4T cells pre-treated with or without TSA for 4 h, then stimulated with P/I for the indicated
times. Nuclei were incubated with MNase and genomic DNA was analysed by PCR using primer set I. The mean and standard error of three
replicate assays are shown.
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The eﬀect of increased histone acetylation on activation
of the GM-CSF gene was then examined. As seen earlier,
GM-CSF mRNA levels increased 450-fold following P/I
stimulation (Figure 4C) and while TSA pre-treatment did
not aﬀect basal GM-CSF mRNA levels, expression in
response to P/I was increased >3-fold by the presence
of TSA (Figure 4C). The P/I response of a control gene,
rhodopsin, which is not normally expressed in T cells was
not facilitated by TSA treatment although TSA alone led
to a small increase in expression (Figure 4D). CHART-
PCR was then used to determine how the increased
histone acetylation levels across the GM-CSF gene
inﬂuenced chromatin remodelling events at the promoter.
As we have observed previously (11), following P/I stimu-
lation little change in accessibility of the promoter to
MNase was seen at 30min or 1 h, but an increase in
accessibility occurred by 4-h post-stimulation (Figure 4E).
However, in TSA pre-treated cells an increase in chro-
matin accessibility was detected as early as 30min post-
stimulation (Figure 4E).
Therefore, increasing histone acetylation across the
GM-CSF promoter resulted in faster kinetics of chroma-
tin remodelling at the promoter in response to P/I
stimulation, which translated into increased mRNA
levels. This suggests that histone hyperacetylation at the
GM-CSF promoter facilitates chromatin remodelling and
subsequent transcriptional activation of the GM-CSF
gene in T cells.
The eﬀect of TSA treatment on the GM-CSF gene in B
cells in which the promoter is normally resistant to P/I-
induced chromatin remodelling and subsequent transcrip-
tional activation was next examined. As seen previously,
P/I treatment could not induce GM-CSF expression in
either A20 or WEHI-231 B cells (Figure 5A and B,
respectively). While TSA treatment alone had a small
eﬀect on GM-CSF mRNA levels, an 200-fold increase in
GM-CSF mRNA levels was observed in both cells lines
in response to P/I stimulation following pre-treatment
with TSA (Figure 5A and B). Furthermore, analysis by
CHART-PCR revealed that following TSA treatment, P/I
stimulation was able to induce chromatin remodelling
across the GM-CSF promoter in A20 B cells (Figure 5C).
Therefore, increasing histone acetylation levels in B cells
removes the block in chromatin remodelling at the GM-
CSF promoter in response to P/I stimulation.
Hyperacetylation and demethylation cooperate to facilitate
activation of the GM-CSF gene in both T and B cells
Although demethylation alone had no eﬀect on GM-CSF
expression in A20 B cells, we next examined whether
demethylation of the promoter had any eﬀect in conjunc-
tion with histone hyperacetylation. As seen earlier, in
EL-4T cells both TSA-induced histone hyperacetylation
and azaC-induced DNA demethylation increased GM-
CSF mRNA expression in response to P/I stimulation,
and GM-CSF mRNA expression was increased even
further by azaC and TSA treatment in combination
(Figure 6A). While azaC treatment had only minimal
eﬀect on GM-CSF gene expression in A20 B cells, TSA
treatment led to increased GM-CSF mRNA levels in
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Figure 5. Histone hyperacetylation relieves the block in GM-CSF gene
activation in B cells. (A) GM-CSF mRNA levels were determined by
PCR analysis of cDNA prepared from A20 B cells treated with or
without TSA for 4 h and then either left unstimulated (NS) or stimu-
lated with P/I for 4 h. The mean and standard error of three replicate
assays are shown. (B) GM-CSF mRNA levels were determined in
WEHI-231 B cells treated as in (A). (C) Nuclei were isolated from A20
B cells treated as in (A). Nuclei were incubated with MNase and
genomic DNA was analysed by PCR using primer set I. The mean
and standard error of three replicate assays are shown.
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response to P/I (Figure 6B) and azaC treatment was again
able to augment P/I-induced GM-CSF mRNA levels in
combination with TSA (Figure 6B).
Put together, these data suggest that demethylation of
the GM-CSF promoter only inﬂuences GM-CSF mRNA
levels in cells in which the promoter has undergone
chromatin remodelling implying that promoter methyla-
tion may aﬀect transcriptional events subsequent to
chromatin remodelling. To test this possibility the GM-
CSF promoter reporter construct was methylated with the
CpG methylase M.SssI prior to transfection into EL-4T
cells. As before basal expression of the unmethylated
GM-CSF reporter was detected, which increased drama-
tically upon P/I stimulation (Figure 6C). In contrast, little
basal or induced expression of the methylated GM-CSF
reporter was detected, suggesting that CpG methylation
inhibits transcriptional activation of the GM-CSF
promoter.
Put together, these data suggest that methylation of the
GM-CSF promoter does not aﬀect chromatin remodelling
events at the promoter, but inﬂuences transcriptional
activation of the GM-CSF gene subsequent to chromatin
remodelling.
Brg1 is enriched at the GM-CSF promoter in T cells,
and is required for efficient gene activation
The chromatin remodelling events at the GM-CSF pro-
moter involving the speciﬁc depletion of histones (13)
facilitated by histone acetylation is reminiscent of the
chromatin remodelling events observed at the Pho5
promoter in yeast (29,38). At the Pho5 promoter histone
depletion is facilitated by the SWI/SNF chromatin
remodelling complex recruited to the promoter via hyper-
acetylated histones (25,26). We, therefore, asked whether
the mammalian SWI/SNF remodelling complex was
associated with the GM-CSF promoter in T cells. ChIP
analysis with antibodies to the SWI/SNF component,
BRG1 was performed on EL-4T cells before and after
stimulation with P/I for 4 h. Immunoprecipitated DNA
was quantiﬁed using PCR primers designed to speciﬁc
regions of the GM-CSF gene (Figure 1A). We found that
in unstimulated cells, relative levels of BRG1 were
2–3-fold higher at the GM-CSF promoter (primer sets
I and +I) than at regions 2 kb distal from the promoter
(primer set 30 and 50) or the GAPDH gene (Figure 7A).
Surprisingly, BRG1 levels decreased at the promoter
following T-cell activation (Figure 7A, set I P=0.037
and set +I P=0.040, paired t-test). In contrast, there was
little change in BRG1 levels associated with the 30 and 50
regions of the gene, or with the constitutively expressed
GAPDH gene following stimulation (Figure 7A).
Since BRG1 is enriched at the GM-CSF promoter in
unstimulated EL-4T cells we speculated that this may be
a requirement for GM-CSF gene activation. Therefore,
association of BRG1 with the GM-CSF promoter was
examined in diﬀerent cell types. As shown above, BRG1
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Figure 6. DNA demethylation facilitates increased transcription of the
GM-CSF gene. (A) EL-4T cells were either left untreated or pre-treated
with azaC then treated with or without TSA prior to stimulation with
PI for 4 h. GM-CSF mRNA levels relative to GAPDH were then
determined by quantitative PCR analysis. The mean and standard error
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was associated with the GM-CSF promoter in unstimu-
lated T cells, with levels decreasing upon stimulation
(Figure 7B). In contrast, little BRG1 was associated with
the GM-CSF promoter in A20 B cells, with relative levels
signiﬁcantly lower than observed in T cells even after
stimulation (Figure 7B). Furthermore, there was no
decrease in BRG1 levels at the GM-CSF promoter in
A20 B cells following stimulation. The diﬀerence in BRG1
levels at the GM-CSF promoter in B and T cells is not due
to diﬀerences in BRG1 expression in these cell types, as
western analysis of nuclear extracts from A20 B cells and
EL-4T cells conﬁrmed equal levels of BRG1 protein in
these cells (Figure 7C). In addition, BRG1 protein levels
did not change in either cell type upon P/I stimulation
(Figure 7C).
The cell-type speciﬁc enrichment of BRG1 at the GM-
CSF promoter correlates with histone acetylation levels
at the promoter in these cell types. We therefore asked
whether BRG1 enrichment at the GM-CSF promoter is
facilitated by histone acetylation. EL-4T cells were treated
with TSA to increase histone acetylation, and BRG1 levels
monitored by ChIP assay. TSA treatment resulted in
increased binding of BRG1 at the GM-CSF promoter
(Figure 7D, set +I), although no increased binding of
BRG1 was detected at an adjacent region (Figure 7D, set
V), where increased acetylation was also observed
(Figure 4B). These data suggest that while increasing
histone acetylation may facilitate BRG1 recruitment to
the GM-CSF promoter, acetylation alone is not suﬃcient
to recruit BRG1.
Enrichment of BRG1 at the GM-CSF promoter corre-
lates with the transcriptional competence of the GM-CSF
gene and the ability of the promoter to undergo
remodelling in response to activating signals. To deter-
mine whether BRG1 is required for GM-CSF promoter
remodelling and gene activation, GM-CSF expression was
monitored in EL-4T cells transfected with an ATPase
BRG1 mutant construct, BRG1K/R (32). This BRG1
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mutant protein has been found to assemble into the SWI/
SNF complex, but is unable to remodel nucleosomes (39).
Cells were transfected with the HA tagged BRG1 mutant
construct along with a truncated Kk.II receptor protein
that enabled sorting of transfected cells. Expression of the
mutant BRG1 protein in EL-4T cells was conﬁrmed by
western blotting with an HA antibody (Figure 8A). Sorted
cells were either left unstimulated or stimulated with P/I
for 6 h and GM-CSF expression monitored by quantita-
tive PCR. GM-CSF mRNA levels increased 500-fold
following P/I stimulation in cells transfected with vector
alone (Figure 8B). In contrast, accumulation of GM-CSF
mRNA was reduced by 50% in cells expressing the BRG1
ATPase mutant, suggesting that BRG1 contributes to
activation of the GM-CSF gene. Basal levels of GM-CSF
expression were unaﬀected in the mutant expressing cells
(data not shown).
To determine whether BRG1 is also required for
chromatin remodelling events at the promoter, transfected
cells were analysed by CHART-PCR. Cells were either left
unstimulated or stimulated with P/I, nuclei isolated and
incubated with MNase. Genomic DNA was then isolated,
and analysed using primer set I that spans the GM-CSF
promoter. In cells transfected with the control plasmid,
an increase in accessibility (20%) was observed follow-
ing stimulation for 2 h with a further increase at 6 h
(Figure 8C). However, while a similar change in accessi-
bility was observed in cells containing the mutant BRG1
protein at 6 h, a considerably smaller change in accessi-
bility was observed at 2 h (Figure 8C), suggesting that
chromatin remodelling at the promoter was delayed in
these cells.
Put together, these data suggest that BRG1 is enriched
at the GM-CSF promoter in unstimulated EL-4T cells
and plays a direct role in chromatin remodelling events
associated with GM-CSF gene activation. Loss of BRG1
from the promoter following stimulation correlates
with depletion of histones from the promoter and the
associated increased accessibility.
DISCUSSION
Activation of the GM-CSF gene in response to T-cell
stimulatory signals involves highly targeted changes in
chromatin structure, involving the depletion of histones
and resulting in increased accessibility across the promoter
and enhancer regions of the gene (11–14). These chroma-
tin changes are a prerequisite for eﬃcient transcriptional
activation of the GM-CSF gene in T cells, and we have
found that these remodelling events are blocked in B cells,
which do not express GM-CSF in response to immune
signals. The chromatin environment of the GM-CSF
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Figure 8. BRG1 is required for GM-CSF gene activation. (A) Nuclear
extracts from EL-4T cells transfected with the pBJ5 plasmid or pBJ5-
BRG1K/R were subjected to SDS–PAGE and analysed by western
blotting with the indicated antibodies. Positions of protein molecular
weight markers are indicated. (B) EL-4T cells transfected with the
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cells using primer set +II. Data were graphed as fold change in mRNA
levels following stimulation. The mean and standard error of three
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promoter is diﬀerentially marked in T cells compared to
B cells, and this appears to at least partially dictate the
ability of the gene promoter to respond to immune stimuli.
The GM-CSF promoter is speciﬁcally marked in unin-
duced T cells by increased histone acetylation and
enrichment of the chromatin remodeller BRG1, and
these marks contribute to the ability of the GM-CSF
promoter to undergo chromatin remodelling in response
to immune signalling.
We found that the methylation status of two CpG sites
located up and downstream from the transcription start
site did not correlate with the response of the gene.
Furthermore, demethylation of the CpG site in the
GM-CSF promoter in B cells by azaC treatment was not
suﬃcient to render the gene responsive to activating
signals and this is likely to be due to the fact that
demethylation of the promoter is not suﬃcient to relieve
the block in chromatin remodelling of the promoter (data
not shown). However, azaC treatment augmented GM-
CSF mRNA expression once the block in chromatin
remodelling had been relieved by TSA treatment. While it
is possible that azaC is indirectly aﬀecting GM-CSF gene
expression, the data presented are also consistent with a
model in which methylation of the promoter CpG site
inhibits binding of transcription factors to the gene
promoter, and therefore inhibits transcriptional activation
of the GM-CSF gene, subsequent to promoter remodel-
ling. This is supported by data demonstrating that a
methylated reporter construct cannot be activated, but
further studies are required to investigate whether
methylation of the CpG site in the promoter aﬀects
transcription factor binding, particularly at the Sp1 site
which contains the methylated CpG. It should also be
noted, however, that the luciferase gene has a 5-fold
higher density of CpG sequences than the GM-CSF gene,
and this density of methylation may itself be suﬃcient to
block activation of a methylated reporter gene plasmid.
Recent studies have demonstrated that chromatin
remodelling events that occur at the GM-CSF promoter
in response to immune signals involve the depletion of
histones from the promoter region. Similar histone
eviction has also been described at the IL-2 gene promoter
following T-cell activation (13) and at the yeast Pho5 and
Pho8 promoters (29,30,38,40). In the case of both Pho5
and Pho8, histone eviction was preceded by a transient
increase in histone acetylation and stimulation-driven
increases in histone acetylation have been found to
accompany activation of a number of other inducible
genes (25,28,29). However, such increases in acetylation
were not observed at the GM-CSF promoter in response
to activation. Instead, the GM-CSF promoter already has
a relatively high degree of histone acetylation in unin-
duced T cells compared to regions upstream or down-
stream to the promoter or compared to the GM-CSF
promoter in B cells. This basal enrichment of histone
acetylation in uninduced T cells may generate an activa-
tion competent environment at the GM-CSF promoter
and obviate the need for stimulation-induced increases
in acetylation. In support of this, artiﬁcially increasing
histone acetylation levels at the GM-CSF promoter in
T cells resulted in more rapid chromatin remodelling of
the promoter and enhanced GM-CSF mRNA expression.
More importantly, treatment of B cells with the histone
deacetylase inhibitor TSA relieved the block in chromatin
remodelling at the GM-CSF promoter, enabling promoter
activation in response to stimulatory signals. Thus, we
would speculate that unlike many other inducible genes
the GM-CSF promoter does not become hyperacetylated
following activation, but rather needs to be constitutively
acetylated to respond to P/I activation signals.
The SWI/SNF complex has been implicated in dis-
placement of nucleosomes at the yeast Pho5 and Pho8
genes. Nucleosome remodelling is inhibited at the Pho8
promoter and signiﬁcantly delayed at the Pho5 promoter
in yeast strains in which the SWI/SNF ATPase snf2 is
mutated (26,27,41). Such a role for the SWI/SNF complex
is also supported by in vitro experiments demonstrating
that the SWI/SNF complex can displace histone octamers
in trans, although this is less eﬃcient than histone sliding
(42). Our ﬁnding that chromatin remodelling at the
GM-CSF promoter is dependent on BRG1 also implicates
the SWI/SNF remodelling complex in histone loss at the
GM-CSF promoter. We found that chromatin remodel-
ling events across the promoter were impaired, but not
completely inhibited in the presence of a BRG1 ATPase
mutant. This may be because wild-type BRG1 protein is
still present in these cells, and not completely competed by
the BRG1 mutant, or may reﬂect the fact that remodelling
can still occur, although less eﬃciently in the absence of
BRG1. A similar situation exists at the Pho5 promoter
where the SWI/SNF complex is required for eﬃcient
histone eviction, but remodelling can still occur in the
absence of the core SNF2 component (43) and has led to
the suggestion that an alternative, although less eﬃcient,
eviction mechanism is operating in these circumstances.
The SWI/SNF complex has been implicated in chro-
matin remodelling events required for activation of a
range of genes (23,24,44), however in such studies, BRG1
has generally been found to be recruited to the gene
promoters in response to stimulatory signals, consistent
with a model in which the SWI/SNF complex is recruited
to gene promoters through DNA bound transcription
factors. In contrast, we observed that BRG1 was con-
stitutively associated with the GM-CSF promoter in
uninduced T cells and then lost from the promoter
concomitant with histone loss in response to T-cell
activation. This raises the question of how the BRG1
protein is speciﬁcally enriched at the GM-CSF promoter
in uninduced EL-4T cells. BRG1 contains a bromodo-
main which can interact with acetylated histones (45) and
its recruitment to the IFNb enhancer as well as the Pho5
and Pho8 promoters is facilitated by histone acetyla-
tion (25,29,46). It is possible, therefore, that BRG1 is
constitutively recruited to the GM-CSF promoter via
histone acetylation. In support of this model, enrichment
of both acetylated histones and BRG1 was observed at the
GM-CSF promoter in uninduced T cells but not B cells.
Furthermore, increasing GM-CSF promoter acetylation
in T cells by TSA treatment resulted in an associated
increase in BRG1 levels at the promoter. However, it is
likely, that BRG1 requires the presence of a constitutive
transcription factor(s) acting together with higher levels of
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acetylation, for recruitment to the promoter in uninduced
T cells because increasing histone acetylation levels was
not suﬃcient to increase BRG1 levels at a distal region of
the gene. The nature of such factors remains to be
determined. It should be noted that these ﬁndings are in
contrast to our previous in vitro studies, which demon-
strated stimulation-induced recruitment of BRG1 to a
GM-CSF template (11), however this previous study used
naked DNA templates and therefore was not able to take
into account interactions between chromatin and BRG1.
The data presented here are consistent with a model in
which the SWI/SNF complex is poised at the GM-CSF
promoter in uninduced T cells and this together with
histone acetylation generates a chromatin environment
which is conducive to rapid remodelling and gene activa-
tion in response to the appropriate cellular signals. Along
this line, analysis of the yeast GAL1 gene demonstrated
that more rapid gene induction was achieved in situations
when the SWI/SNF complex is already poised at the gene
promoter (47).
It is becoming apparent that activation of inducible
genes in response to stimulatory signals involves a series
of precisely orchestrated events aimed at remodelling
nucleosomes positioned over the promoter so that trans-
cription can occur. Activation of the GM-CSF gene
occurs relatively rapidly in response to immune signals,
but cannot be induced in B cells by these same signals.
We propose that this is because the gene promoter is
speciﬁcally poised for remodelling in T cells by high basal
levels of histone acetylation and the constitutive recruit-
ment of the SWI/SNF complex, which create an environ-
ment conducive to gene activation. These data
demonstrate that the epigenetic status of the GM-CSF
promoter varies between cell types and dictates its
potential for activation.
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